Vanguard Group Inc. Has $5.87 Million Position in Catalyst Pharmaceuticals, Inc. (CPRX)

Vanguard Group Inc. raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 0.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,007,935 shares of the biopharmaceutical company’s stock after purchasing an additional 15,600 shares during the quarter. Vanguard Group Inc. owned approximately 3.63% of Catalyst Pharmaceuticals worth $5,865,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Knott David M acquired a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at approximately $554,000. JPMorgan Chase & Co. acquired a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at approximately $155,000. Bank of New York Mellon Corp lifted its position in shares of Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,404 shares during the last quarter. Finally, Oxford Asset Management lifted its position in shares of Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 34,181 shares during the last quarter. Hedge funds and other institutional investors own 40.15% of the company’s stock.

Several analysts recently weighed in on the company. Zacks Investment Research cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Piper Jaffray Companies set a $6.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 7th. Roth Capital set a $5.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 10th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and set a $5.00 price target on shares of Catalyst Pharmaceuticals in a report on Tuesday, September 5th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $4.90.

Catalyst Pharmaceuticals, Inc. (NASDAQ CPRX) opened at 2.44 on Friday. The company’s market cap is $206.31 million. The firm’s 50-day moving average price is $2.70 and its 200-day moving average price is $2.29. Catalyst Pharmaceuticals, Inc. has a 1-year low of $0.94 and a 1-year high of $3.20.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Equities research analysts forecast that Catalyst Pharmaceuticals, Inc. will post ($0.23) EPS for the current fiscal year.

In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany acquired 20,000 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was purchased at an average price of $2.58 per share, with a total value of $51,600.00. Following the transaction, the insider now directly owns 4,471,026 shares in the company, valued at approximately $11,535,247.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 8.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by BBNS and is the property of of BBNS. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/vanguard-group-inc-buys-15600-shares-of-catalyst-pharmaceuticals-inc-cprx/1603772.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game


Leave a Reply

 
© 2006-2017 BBNS.